Regional Cerebral Glucose Metabolism After Pridopidine (ACR16) Treatment in Patients With Huntington Disease

被引：13

作者：

Esmaeilzadeh, Mouna ^{[1
]}

Kullingsjo, Johan ^{[2
]}

Ullman, Henrik ^{[2
]}

Varrone, Andrea

Tedroff, Joakim ^{[2
]}

机构：

[1] Karolinska Inst, Stockholm Brain Inst, Dept Clin Neurosci, Karolinska Univ Hosp,PET Ctr, SE-17176 Stockholm, Sweden

[2] NeuroSearch Sweden AB, Stockholm, Sweden

来源：

CLINICAL NEUROPHARMACOLOGY | 2011年 / 34卷 / 03期

关键词：

Huntington disease; FDG PET imaging; brain metabolism; ACR16; pridopidine; PARKINSONS-DISEASE; PET; TASK;

D O I：

10.1097/WNF.0b013e31821c31d8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objectives: Huntington disease is a hereditary neurodegenerative disorder resulting in loss of motor, cognitive, and behavioral functions and is characterized by a distinctive pattern of cerebral metabolic abnormalities. Pridopidine (ACR16) belongs to a novel class of central nervous system compounds in development for the treatment of Huntington disease. The objective of the study was to investigate the metabolic changes in patients with Huntington disease before and after pridopidine treatment. Methods: [(18)F] Fluorodeoxyglucose positron emission tomographic imaging was used to measure the regional cerebral metabolic rate of glucose at baseline and after 14 days of open-label pridopidine treatment in 8 patients with Huntington disease. Clinical assessments were performed using the Unified Huntington's Disease Rating Scale. Results: Statistical parametric mapping analysis showed increased metabolic activity in several brain regions such as the precuneus and the mediodorsal thalamic nucleus after treatment. In addition, after pridopidine treatment, the correlation between the clinical status and the cerebral metabolic activity was strengthened. Conclusions: Our findings suggest that pridopidine induces metabolic changes in brain regions implicated as important for mediating compensatory mechanisms in Huntington disease. In addition, the finding of a strong relationship between clinical severity and metabolic activity after treatment also suggests that pridopidine treatment targets a Huntington diseaseYrelated metabolic activity pattern.

引用

页码：95 / 100

页数：6

共 31 条

[1] Selective neurodegeneration in Huntington's disease [J].

Albin, RL .

ANNALS OF NEUROLOGY, 1995, 38 (06) :835-836

[2] Striatal glucose metabolism and dopamine D-2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease [J].

Antonini, A ;

Leenders, KL ;

Spiegel, R ;

Meier, D ;

Vontobel, P ;

WeigellWeber, M ;

SanchezPernaute, R ;

deYebenez, JG ;

Boesiger, P ;

Weindl, A ;

Maguire, RP .

BRAIN, 1996, 119 :2085-2095

[3]

DEYEBENES J, 2010, 14 INT C PARK DIS MO

[4] The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties [J].

Dyhring, Tino ;

Nielsen, Elsebet O. ;

Sonesson, Clas ;

Pettersson, Fredrik ;

Karlsson, Jonas ;

Svensson, Peder ;

Christophersen, Palle ;

Waters, Nicholas .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 628 (1-3) :19-26

[5] Metabolic correlates of pallidal neuronal activity in Parkinson's disease [J].

Eidelberg, D ;

Moeller, JR ;

Kazumata, K ;

Antonini, A ;

Sterio, D ;

Dhawan, V ;

Spetsieris, P ;

Alterman, R ;

Kelly, PJ ;

Dogali, M ;

Fazzini, E ;

Beric, A .

BRAIN, 1997, 120 :1315-1324

[6]

Eriksson L, 2006, BASIC PRINCIPLES APP

[7]

ESMAEILZADEH M, HUM BRAIN M IN PRESS

[8] Thalamic metabolism and symptom onset in preclinical Huntington's disease [J].

Feigin, A. ;

Tang, C. ;

Ma, Y. ;

Mattis, P. ;

Zgaljardic, D. ;

Guttman, M. ;

Paulsen, J. S. ;

Dhawan, V. ;

Eidelberg, D. .

BRAIN, 2007, 130 :2858-2867

[9] Preclinical Huntington's disease: Compensatory brain responses during learning [J].

Feigin, A ;

Ghilardi, MF ;

Huang, CR ;

Ma, YL ;

Carbon, M ;

Guttman, M ;

Paulsen, JS ;

Ghez, CP ;

Eidelberg, D .

ANNALS OF NEUROLOGY, 2006, 59 (01) :53-59

[10]

Feigin A, 2001, J NUCL MED, V42, P1591

← 1 2 3 4 →